Literature DB >> 30033637

Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.

Kohei Ogawa1, Kenya Kamimura1, Shuji Terai1.   

Abstract

Entities:  

Year:  2018        PMID： 30033637     DOI： 10.1002/hep.30189

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  8 in total

1.  Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.

Authors:  Emanuel Raschi; Alessandra Mazzarella; Ippazio Cosimo Antonazzo; Nicolò Bendinelli; Emanuele Forcesi; Marco Tuccori; Ugo Moretti; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

Review 2.  [Severe secondary sclerosing cholangitis as manifestation of a very rare underlying disease].

Authors:  Britta Franziska Zecher; Roman Zenouzi; Melanie Lang; Panagiotis Karagiannis; Till Clauditz; Lutz Fischer; Martina Sterneck; Christoph Schramm; Ansgar W Lohse; Marcial Sebode
Journal:  Internist (Berl)       Date:  2021-09-21       Impact factor: 0.743

Review 3.  Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings.

Authors:  Ryota Nakano; Hideyuki Shiomi; Aoi Fujiwara; Kohei Yoshihara; Ryota Yoshioka; Shoki Kawata; Shogo Ota; Yukihisa Yuri; Tomoyuki Takashima; Nobuhiro Aizawa; Naoto Ikeda; Takashi Nishimura; Hirayuki Enomoto; Hiroko Iijima
Journal:  Healthcare (Basel)       Date:  2022-04-20

4.  Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.

Authors:  Borui Pi; Jin Wang; Yifan Tong; Qiao Yang; Fangfang Lv; Yunsong Yu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

5.  A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis.

Authors:  Ryunosuke Ooi; Kazunori Tobino; Mitsukuni Sakabe; Takafumi Kawabata; Yuri Hiramatsu; Takuto Sueyasu; Kohei Yoshimine
Journal:  Respir Med Case Rep       Date:  2020-08-25

6.  Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients.

Authors:  Koji Imoto; Motoyuki Kohjima; Tomonobu Hioki; Tomoyuki Kurashige; Miho Kurokawa; Shigeki Tashiro; Hideo Suzuki; Akifumi Kuwano; Masatake Tanaka; Seiji Okada; Masaki Kato; Yoshihiro Ogawa
Journal:  Can J Gastroenterol Hepatol       Date:  2019-12-17

7.  IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.

Authors:  Stephanie Stein; Lara Henze; Tobias Poch; Antonella Carambia; Till Krech; Max Preti; Fenja Amrei Schuran; Maria Reich; Verena Keitel; Romina Fiorotto; Mario Strazzabosco; Lutz Fischer; Jun Li; Luisa Marie Müller; Jonas Wagner; Nicola Gagliani; Johannes Herkel; Dorothee Schwinge; Christoph Schramm
Journal:  J Hepatol       Date:  2020-11-13       Impact factor: 25.083

8.  A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.

Authors:  Yuya Hirasawa; Kiyoshi Yoshimura; Hiroto Matsui; Yutaro Kubota; Hiroo Ishida; Jun Arai; Masashi Sakaki; Nao Oguro; Midori Shida; Makoto Taniguchi; Kazuyuki Hamada; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Ryotaro Ohkuma; Takehiko Sambe; Atsushi Horiike; Chiyo K Imamura; Eisuke Shiozawa; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Genshu Tate; Shinichi Kobayashi; Takuya Tsunoda
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.